• Dec. 20, 2016, 12:40 PM
    Dec. 20, 2016, 12:40 PM
  • Dec. 20, 2016, 9:16 AM
    Dec. 20, 2016, 9:16 AM | 1 Comment
  • Dec. 20, 2016, 8:49 AM
    • Thinly traded micro cap Akebia Therapeutics (NASDAQ:AKBA) is up 32% premarket on increased volume in response to its announcement of a collaboration and license agreement with Otsuka Pharmaceutical (OTCPK:OTSKF)(OTCPK:OTSKY) in the U.S. for lead product candidate vadadustat.
    • Under the terms of the deal, Akebia will receive $265M in committed funds plus milestones that could value the transaction at more than $1B. The committed capital includes an upfront payment of $125M, a $35M payment in Q1 2017 and $105M in development costs. The partners will contribute equally to commercialization efforts and will also equally share all costs and revenue.
    • Vadadustat (AKB-6548), under initial development for the treatment of anemia in patients with chronic kidney disease, is an inhibitor of hypoxia inducible factor (HIF)-prolyl hydroxylase, an enzyme that promotes the breakdown of HIF proteins. HIF is the primary regulator of the production of red blood cells. The body's natural response to anemia is to increase the level of HIF proteins.
    Dec. 20, 2016, 8:49 AM | 1 Comment
  • Dec. 16, 2016, 4:30 PM
    Dec. 16, 2016, 4:30 PM | 10 Comments
  • Dec. 12, 2016, 9:17 AM
    • Akebia Therapeutics (NASDAQ:AKBA) announces that the Opposition Division (OD) of the European Patent Office (EPO) has revoked another of FibroGen's HIF-related patents. The patent, EP 1 633 333 (the ’333 patent), claimed various compounds that were purported to stabilize HIFα for treating or preventing various conditions, including iron deficiency and specific forms of anemia. This ruling follows Akebia’s challenge to FibroGen’s earlier European patent, EP 1 463 823, which was revoked in its entirety by the OD earlier this year.
    • In August 2014, the EPO granted the ’333 patent to FibroGen. In order to preserve the right to challenge this patent, on May 20, 2015, Akebia filed an opposition to the ’333 patent requesting that the ’333 patent be revoked in its entirety.
    • In an oral proceeding on December 8 and 9, the OD ruled that the patent as granted did not meet the requirements for patentability under the European Patent Convention and, therefore, revoked the patent in its entirety. The written decision consistent with the oral ruling is expected within a couple of months.
    Dec. 12, 2016, 9:17 AM | 1 Comment
  • Nov. 9, 2016, 4:49 PM
    Nov. 9, 2016, 4:49 PM
  • Sep. 30, 2016, 7:54 AM
    • Zoetis (NYSE:ZTS) initiated wit Buy rating with a $60 (18% upside) price target by Bank of America.
    • Akebia Therapeutics (NASDAQ:AKBA) initiated with Buy rating and $18 (106% upside) price target by Brean Capital.
    • DexCom (NASDAQ:DXCM) initiated with Neutral rating and $97 (10% upside) price target by B. Riley.
    • vtv Therapeutics (NASDAQ:VTVT) initiated with Buy rating and $13 (82% upside) price target by H.C. Wainwright.
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Outperform rating by Leerink Swann.
    • Aldeyra Therapeutics (NASDAQ:ALDX) initiated with Buy rating and $18 (139% upside) price target by H.C. Wainwright.
    • Lantheus Holdings (NASDAQ:LNTH) initiated with Neutral rating and $8 (1% upside) price target by Credit Suisse.
    • BioTime (NYSEMKT:BTX) initiated with Buy rating and $6 (63% upside) price target by Ladenburg.
    • Sanofi (NYSE:SNY) initiated with Neutral rating by Piper Jaffray.
    Sep. 30, 2016, 7:54 AM
  • Aug. 8, 2016, 4:55 PM
    • Akebia (NASDAQ:AKBA): Q2 EPS of -$0.95 misses by $0.38.
    • Cash and equivalents of $188.64M
    • Press Release
    Aug. 8, 2016, 4:55 PM | 1 Comment
  • May 5, 2016, 5:40 PM
    • Akebia (NASDAQ:AKBA): Q1 EPS of -$0.70 misses by $0.27.
    May 5, 2016, 5:40 PM
  • Mar. 14, 2016, 4:11 PM
    • Akebia (NASDAQ:AKBA): Q4 EPS of -$0.66 misses by $0.38.
    Mar. 14, 2016, 4:11 PM | 3 Comments
  • Mar. 9, 2016, 1:11 PM
    • Akebia Therapeutics (AKBA +2%) prevails in its vadadustat-related patent fight in Europe by virtue of the total revocation of competitor FibroGen's (FGEN -2.2%) European patent EP 1 463 823 ('823) by the European Patent Office's (EPO) Opposition Division (OD). In an oral session, the OD ruled that the '823 patent did not meet the requirements for patentability under the European Patent Convention. A written decision should be issued within the next several months.
    • The company filed its opposition to the '823 patent in December 2013 after the EPO granted the patent in June 2013.
    • Vadadustat (AKB-6548), under initial development for the treatment of anemia in patients with chronic kidney disease, is an inhibitor of hypoxia inducible factor (HIF)-prolyl hydroxylase (PH), an enzyme that promotes the breakdown of HIF proteins. HIF is the primary regulator of the production of red blood cells. The body's natural response to anemia is to increase the level of HIF proteins.
    • FibroGen's HIF-PH inhibitor is a similar compound called roxadustat.
    Mar. 9, 2016, 1:11 PM
  • Jan. 7, 2016, 9:15 AM
    Jan. 7, 2016, 9:15 AM | 20 Comments
  • Jan. 7, 2016, 7:04 AM
    • Akebia Therapeutics (NASDAQ:AKBA) prices its public offering of 7.25M shares of common stock at $9 per share. Underwriters over-allotment is an additional 1,087,500 shares. Closing date is January 12.
    • Net proceeds will be ~$61M.
    • Shares are down 13% premarket on increased volume.
    Jan. 7, 2016, 7:04 AM
  • Jan. 6, 2016, 5:39 PM
    • Top gainers, as of 5.25 p.m.: ZUMZ +12.1%. M +3.5%. EARS +3.5%. OSUR +2.0%. OME +2.0%.
    • Top losers, as of 5.25p.m.: PER -11.8%. ARDX -7.1%. GMED -5.8%. AKBA -5.1%. EPZM -4.5%.
    Jan. 6, 2016, 5:39 PM
  • Jan. 5, 2016, 12:40 PM
    Jan. 5, 2016, 12:40 PM | 5 Comments
  • Jan. 4, 2016, 5:02 PM
    • Akebia Therapeutics (NASDAQ:AKBA) commences a $75M public offering of common stock. Volume, price and terms have yet to be announced.
    • Net proceeds will fund the continued development of vadadustat in anemic patients with chronic kidney disease, the PRO2TECT program, the INNO2VATE Phase 3 study, the advancement of AKB-6899 through Phase 1, working capital and general corporate purposes.
    Jan. 4, 2016, 5:02 PM